How Can We Address the Corruption Problem in Clinical Trials?

Justin Karter
1
268

Recently, major researchers, including David Healy, Jon Juriedini, Mickey Nardo, and their colleagues, have brought a great deal of attention to issues of corruption in psychiatric research through their reanalysis of industry-funded trials for psychiatric drugs. This week, fellow reformer and former chair of Duke University’s psychiatry department, Bernard Carroll offers a proposal for addressing these issues through the independent analysis of clinical trial data.

Full Text →

Dr. Bernard Carroll is the scientific director of the non-profit Pacific Behavioral Research Foundation and a former chair of Duke University's psychiatry department.
Dr. Bernard Carroll is the scientific director of the non-profit Pacific Behavioral Research Foundation and a former chair of Duke University’s psychiatry department.

 

*

For more see MIA founder Robert Whitaker and psychologist Lisa Cosgrove’s recent book, “Psychiatry Under the Influence,” which thoroughly documented the myriad mechanisms of institutional corruption connecting Big Pharma, academic psychiatry, and the FDA

Previous articleBrexit and Mental Health Europe
Next articleDear Boston Globe: You Are the Failure You Describe
Justin Karter
MIA Research News Editor: Justin Karter is a writer, researcher and community organizer with graduate degrees in both journalism and community psychology. He is a doctoral candidate in Counseling Psychology at UMass Boston, an active member of the Society for Humanistic Psychology, and is currently working on several scholarly projects at the intersection of psychology, social theory, and political philosophy.

1 COMMENT

  1. Years ago, Abram Hoffer suggested creating a government institution that would only test clinical claims. The employees would have no ties to industry and do nothing except this work of evaluation of others’ studies and claims, reporting their results to their government overseers.

LEAVE A REPLY